Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. British Journal Of Cancer 2022, 128: 21-29. PMID: 36289372, PMCID: PMC9814154, DOI: 10.1038/s41416-022-01991-4.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedCarboplatinHumansMaleProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantConceptsProgression-free survivalPhase Ib studyDNA damage repairOverall survivalSafety profileMedian radiographic progression-free survivalMetastatic castration-resistant prostate cancerOpen-label phase Ib studyIb studyDNA damage repair alterationsRadiographic progression-free survivalPD-1/PD-L1 inhibitorsCastration-resistant prostate cancerTreatment-related adverse eventsMedian response durationAndrogen receptor inhibitorsMedian OSSipuleucel-TProlonged OSPretreated populationSurvival benefitPrimary endpointProstate cancerSecondary endpointsAndrogen receptor